Will This ETF Beat the Market Over the Next 12 Months?
2024 was another banner year for the US stock market,…
Buy
52
HUMA Quote, Financials, Valuation and Earnings
Last price:
$5.10
Seasonality move
:
14.43%
Day range:
$5.01 - $5.25
52-week range:
$2.48 - $9.97
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
20.04x
Volume:
3.9M
Avg. volume:
6.2M
1-year change:
91.01%
Market cap:
$656.2M
Revenue:
--
EPS (TTM):
-$1.34
Analysts' Opinion
-
Consensus RatingHumacyte has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.71, Humacyte has an estimated upside of 168.91% from its current price of $5.10.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $6.00 representing 100% downside risk from its current price of $5.10.
Fair Value
-
According to the consensus of 6 analysts, Humacyte has 168.91% upside to fair value with a price target of $13.71 per share.
HUMA vs. S&P 500
-
Over the past 5 trading days, Humacyte has underperformed the S&P 500 by -3.13% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Humacyte does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Humacyte has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Humacyte reported revenues of --.
Earnings Growth
-
Humacyte has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Humacyte reported earnings per share of -$0.33.
Enterprise value:
635.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-6.89x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$85.4M | -$91.5M | -$112.5M | -$24.6M | -$30.2M | |
| EBITDA | $48.4M | -$74.9M | -$137.2M | -$22.7M | -$35M | |
| Diluted EPS | $0.32 | -$0.87 | -$1.34 | -$0.25 | -$0.33 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $244.2M | $174.6M | $102.9M | $23M | |
| Total Assets | -- | $303.4M | $226.2M | $149.4M | $114.8M | |
| Current Liabilities | -- | $21.2M | $17.9M | $15.1M | $20.9M | |
| Total Liabilities | -- | $227.5M | $107.5M | $112.4M | $178.5M | |
| Total Equity | -- | $75.9M | $118.7M | $37M | -$63.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$73.6M | -$73.2M | -$90.6M | -$13M | -$22.9M | |
| Cash From Investing | -$8.4M | $5.2M | -$1.7M | -$493K | -$934K | |
| Cash From Financing | $5.3M | $4.6M | $62.8M | -$764K | $849K | |
| Free Cash Flow | -$74M | -$76M | -$92.3M | -$13.5M | -$23.8M | |
HUMA
Sector
Market Cap
$656.2M
$48.6M
Price % of 52-Week High
51.15%
47.39%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
91.01%
-33.25%
Beta (5-Year)
--
0.754
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$5.05
200-day SMA
Sell
Level
$5.50
Bollinger Bands (100)
Sell
Level
4.54 - 5.98
Chaikin Money Flow
Sell
Level
-168.5M
20-day SMA
Buy
Level
$4.52
Relative Strength Index (RSI14)
Buy
Level
56.37
ADX Line
Buy
Level
39.87
Williams %R
Neutral
Level
-49.1176
50-day SMA
Buy
Level
$4.79
MACD (12, 26)
Buy
Level
0.14
25-day Aroon Oscillator
Buy
Level
4
On Balance Volume
Neutral
Level
68.3M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Stock Forecast FAQ
In the current month, HUMA has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The HUMA average analyst price target in the past 3 months is $13.71.
-
Where Will Humacyte Stock Be In 1 Year?
According to analysts, the consensus estimate is that Humacyte share price will rise to $13.71 per share over the next 12 months.
-
What Do Analysts Say About Humacyte?
Analysts are divided on their view about Humacyte share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Humacyte is a Sell and believe this share price will drop from its current level to $6.00.
-
What Is Humacyte's Price Target?
The price target for Humacyte over the next 1-year time period is forecast to be $13.71 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is HUMA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Humacyte is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HUMA?
You can purchase shares of Humacyte via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Humacyte shares.
-
What Is The Humacyte Share Price Today?
Humacyte was last trading at $5.10 per share. This represents the most recent stock quote for Humacyte. Yesterday, Humacyte closed at $5.10 per share.
-
How To Buy Humacyte Stock Online?
In order to purchase Humacyte stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Carlos Slim Buy PBF Energy?
Carlos Slim made a splash in a surprising sector last…
Is Booking Holdings Stock Undervalued?
There is a lot of humdrum in the market about…
Stock Ideas
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 116x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Sell
39
DOGZ alert for Jan 4
Dogness (International) [DOGZ] is down 20.52% over the past day.
Buy
66
DMRC alert for Jan 4
Digimarc [DMRC] is up 16.19% over the past day.
Sell
30
MSTR alert for Jan 4
MicroStrategy [MSTR] is up 13.33% over the past day.
